Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE002 (USA) (Dr. Nolan)
· consented 2022-08-28
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 88); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2022-12-17 (study day 96); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-26 (study day 105); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 117); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-02-28 (study day 169); relationship: N
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-10 (study day 301); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.